TECLens, Inc announced the treatment of the initial patient for its first-in-human clinical trial evaluating the company's quantitative corneal crosslinking (qCXL) technology for noninvasive refractive vision correction. According to a press release, the clinical study will evaluate the safety and efficacy of TECLens' proprietary CXLens system, which provides personalized, patterned ultraviolet light to reshape the cornea while preserving the epithelium. Specifically, the study will focus on patients with refractive errors, with particular emphasis on presbyopia correction.

The company noted that unlike traditional surgical refractive procedures that cut or remove tissue, qCXL creates new molecular bonds in precise locations. These new bonds strengthen the cornea in these targeted areas, causing it to reshape to improve vision. The CXLens system relies on a proprietary treatment planning engine that is designed to help physicians create personalized precision plans, and real-time ultrasound monitoring to ensure precise execution to the plan.

According to the company, the noninvasive, epithelium-on treatment can be performed in office. The CXLens system's design features a scleral UV delivery that eliminates the need for a speculum. The treatment's real-time biomechanical monitoring tracks the cornea's response throughout the procedure, automatically concluding when the desired correction is achieved, the company said.